Madrigal Pharmaceuticals (MDGL) Cash & Equivalents (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Cash & Equivalents for 17 consecutive years, with $292.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents rose 57.22% year-over-year to $292.7 million; the TTM figure through Jun 2026 stood at $292.7 million (up 57.22% YoY), while the FY2025 annual figure was $198.7 million, up 98.66% from the prior year.
• Cash & Equivalents advanced to $292.7 million in Q2 2026 per MDGL's latest filing, from $227.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $622.5 million in Q1 2024 and bottomed at $42.3 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $204.0 million across 5 years, with a median of $184.9 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 814.14% — and 2025, when it slumped 70.5%.
• Madrigal Pharmaceuticals' Cash & Equivalents stood at $331.5 million in 2022, then slumped by 69.86% to $99.9 million in 2023, then increased by 0.1% to $100.0 million in 2024, then surged by 98.66% to $198.7 million in 2025, then jumped by 47.33% to $292.7 million in 2026.
• Business Quant data shows MDGL's Cash & Equivalents at $292.7 million in Q2 2026, $227.0 million in Q1 2026, and $198.7 million in Q4 2025.